A small Pennsylvania biotech company is planning to start injecting healthy volunteers with a potential coronavirus vaccine this week, after having received regulatory clearance to start clinical testing, reports Business insider
Researchers plan to dose the first person on Monday. The experimental vaccine was developed by Inovio Pharmaceuticals, and the effort has received funding from the Bill and Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations.
The company is enrolling up to 40 healthy adult participants in Philadelphia, at the University of Pennsylvania’s medical school, and in Kansas City, Missouri, at the Center for Pharmaceutical Research.
Each volunteer will receive two doses of the vaccine, four weeks apart. Inovio said it expects quick enrollment in the study and safety results by late summer. If those results are positive, the company will start another study focused on assessing the vaccine’s efficacy against the virus, adds the article.
Given the unprecedented global demand, any vaccine that proves to be safe and effective will face a major challenge in manufacturing.
Inovio said it was scaling up its production capabilities and aiming to have 1 million doses available by the end of 2020, which could be used in additional clinical trials or for emergencies.
During a ceremony marking the 25th anniversary of the passing of Habib Bourguiba in Monastir on…
The parliamentary group of the Justice and Development Party (PJD) has raised concerns regarding the…
In a recent official statement, the National Order of Physicians of Tunisia has called on…
The Tunisair flight TU999, scheduled to depart from Nice at 16:35 (French time) on April…
The New York Times has released a video showing the killing of aid workers in…
The Criminal Division of the Tunis Court of Appeal found the defendants guilty in the…
This website uses cookies.